Pulmonary Hypertension Program

The Pulmonary Hypertension Program, based at the nationally renowned Mount Sinai Hospital in New York City, is a premier, comprehensive care center for patients afflicted with pulmonary hypertension. Consisting of pulmonologists, cardiologists, rheumatologists, clinical nurse specialists, pharmacists, nutritionists, and social workers, our program uses a multidisciplinary approach to provide comprehensive diagnostic and therapeutic services to patients with all forms of pulmonary hypertension, including pulmonary arterial hypertension.

Many aspects of our program have been integrated with the other large, reputable pulmonary hypertension programs within the Mount Sinai Health System, including The Mount Sinai Hospital and Mount Sinai Downtown-Union Square.

Our pulmonary hypertension program offers and has extensive experience using all FDA-approved medications to treat pulmonary hypertension, including oral, inhaled, subcutaneous, and intravenous medications. We are dedicated to providing and maintaining the highest standard of acute as well as chronic care, utilizing not only proven effective treatments but also, where appropriate, new and pioneering therapy.

Types and Causes of Pulmonary Hypertension

Patients with pulmonary hypertension fall under the category of one of five groups. These groups are:

Group 1 – Pulmonary Arterial Hypertension

  • Congenital heart disease
  • Connective Tissue Disease (scleroderma, lupus, etc.)
  • Drug and toxin Induced
  • Familial
  • HIV
  • Idiopathic
  • Portal Hypertension

Group 2 – Left Heart Disease

This is often a result of:

  • Age
  • Coronary artery disease
  • Damage to the heart muscle
  • Diabetes
  • Heart valve disease
  • High blood pressure
  • Obesity

Group 3 – Lung Disease

Pulmonary vessels are tightened in response to other lung diseases, such as:

  • COPD
  • Interstitial lung disease

Group 4 – Chronic Thromboembolic Pulmonary Hypertension

PH caused by old, organized blood clots in the lungs that form a physical barrier to blood flow within the pulmonary arteries.

Group 5 – PH Resulting from Unclear Multifactorial Mechanisms

These diseases include:

  • Blood disease (sickle cell anemia, chronic hemolytic anemia, etc.)
  • History of spleen removal
  • Kidney disease
  • Metabolic disease (Gaucher disease, thyroid disease)
  • Sarcoidosis

Treatments for Pulmonary Hypertension

We offer multiple treatment options for all forms of pulmonary hypertension. Medications such as pills, inhalers, and infusions developed specifically for the treatment of PH to dilate, and reduce the inappropriate growth of cells in the pulmonary arteries. These therapies ultimately allow the heart to function more efficiently.  

Why Mount Sinai

Our program takes a multidisciplinary and patient-centered approach to the management of pulmonary hypertension. We ensure that patients fully understand the nature of their condition and its treatment.

Our program offers and has extensive experience using all FDA-approved medications to treat pulmonary hypertension, including oral, inhaled, subcutaneous, and intravenous medications.